Iovance Biotherapeutics Inc. – which is banking on progressing novel tumor infiltrating lymphocytes for the treatment of solid tumors – saw its shares leap on Tuesday amid media reports it is exploring a sale and has held preliminary talks with potential buyers.
Formerly known as Lion Biotechnologies, Iovance specializes in cell therapy focused on treating solid tumors, and is developing cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), in which immune cells are extracted from a patient’s tumor, expanded and then those cells are infused back into the patient to